Medicines for Europe | Events | Contacts | Privacy Policy
JOINT 22nd MEDICINES FOR EUROPE AND
19th IGBA ANNUAL CONFERENCE
DUBROVNIK

The global value of generic, biosimilar
and value added medicines

Join ALSO THE CEE WORKSHOP on 8 JuNE 2016
click here for the programme and how to register AS SEATS ARE LIMITED

8-10 JUNE 2016
Radisson Blu Dubrovnik Sun Gardens Resort, Orasac-Dubrovnik | CROATIA
 
DIRECT FLIGHTS from Amsterdam,
Frankfurt, London, Paris etc

2016 PROGRAMME

CEE PROGRAMME
Open only to conference registered delegates

REGISTER NOW

ACCOMMODATION: There are still bedrooms available at the conference hotel against the best available rate clicking here.
If you are attending with more colleagues there is also an option to book a 2 bedroom apartment. To do so, please send an email directly to the hotel via: events.dubrovnik@radissonblu.com to the attention of Sandro Zoričić, mentioning you are an attendee of the conference. In alternative you might want to check the availability of www.booking.com

ADVERTISING, EXHIBITION & SPONSORSHIP OPPORTUNITIES

SHARE THIS PAGE

Join the Generics Bulletin Survey clicking here! You can win a mini iPad at our Annual Conference in Dubrovnik!!!

Full (4.05 min) version of the video click here

Summary (2.52 min) version of video click here

WITH THE PARTICIPATION OF

Jeremy Desai
CEO & President, Apotex

The global value of generic, biosimilar and value added medicines

For the first time, Medicines for Europe and IGBA join forces to create an opportunity to learn about global developments in generic, biosimilar and value added medicines. Our joint 22nd Medicines for Europe and 19th IGBA Annual Conference delivers a unique platform for you to meet and network with industry, regulators and key stakeholders from all over the world.

At the 2016 Conference in Dubrovnik, attendees will have the opportunity to:
* Discover new strategic business opportunities
* Gain insight into the latest market developments
* Discuss sustainable healthcare systems with payers, regulators and policy makers

Last year’s EGA Annual Conference in Berlin was attended by 250 delegates representing more than 190 companies and organisations from over 30 different countries worldwide. To secure your place at this ‘must attend’ event, please register now and you too can share information with leading experts and network with your industry peers.

Follow the event on Twitter #IGBAEGA2016


TOPICS

  • Learn about the major differences between marketing generic vs biosimilar medicines.
  • What are today the key barriers and drivers to biosimilar uptake?
  • Learn about the incredible innovation happening in our industry that will improve healthcare for all.
  • What makes a generic and biosimilar industrial sector an asset for patients, the healthcare community and governments?
  • What is the difference between a complex to make generic and a value added medicine?
  • Learn about the current market trends in the generic and biosimilar medicines industry for developed countries.
  • How can we create more predictable pricing models for essential generic medicines which are the backbone of healthcare?
  • What are the government policies that can boost your manufacturing opportunities?
  • An overview of ongoing regulatory cooperation initiatives: IGDRP, ICH, Biosimilars Cluster, TTIP regulatory convergence
  • How does regulatory convergence concretely impact my development?
  • Learn how your company can get involved in regulatory cooperation projects

  • What’s the impact of counterfeit and falsified medicines in the world? What is the risk for patients and for the reputation of your company?
  • How can companies make a difference in the fight against counterfeiting?
  • Learn about how leading industry CEOs plan to deliver on access in a challenging economic and political environment
  • People are living longer: what does this mean for your product portfolio and future development? Can this industry continue its role as the backbone of medicines supply for healthcare?
  • Learn about generic medicines markets in Brazil, Mexico, Middle East, North Africa and South Africa
  • What are the major socio-economic trends affecting healthcare? Ageing populations, chronic disease development, etc.
  • Learn about how to create sustainable and continuous access to medicines for patients in hospitals.
  • How to develop intelligence on hospital market reforms and their impact on your business?
  • How can regulatory cooperation strengthen the international supply chain of generic medicines?
  • Where does the role of the industry gives way to the one of governments & regulators?
  • Through real case studies, learn how to maximise the use of digital technology to educate and inform about the benefits of generic, biosimilar and value added medicines.

WHO SHOULD ATTEND 

  • International Generic and Biosimilar Medicines Industry
  • National, European and International Authority Representatives
  • Pharmaceutical Sector Analysts and Consultants
  • Investment Bankers
  • Pharmaceutical Wholesalers
  • Consultants and Service Providers
  • API Manufacturers

  • Law Firms - Patent Litigation Specialists
  • Pharmaceutical Distributors
  • Academia
  • Healthcare Professionals
  • Health Insurers
  • Medical Societies
  • Patient Organisations

Join the FMD PAVILLION! More info click here

with the participation of


WHAT DELEGATES SAID ABOUT THE EGA 2015 EDITION: 


LIST OF COMPANIES AND ORGANISATIONS PRESENT IN THE EGA EVENT 2015

CONFERENCE FLYER

CHAIRPERSONS AND SPEAKERS


About the IGPA now IGBA

The International Generic and Biosimilar Medicines Association (IGBA) was founded as IGPA (International Generic Pharmaceutical Alliance) in March 1997 to strengthen cooperation between associations representing manufacturers of generic medicines. Its membership includes the Medicines for Europe (formerly EGA - Europe), the CGPA (Canada), the GPhA (USA), the JAPM (Jordan), the NAPM (South Africa), the TGPA (Taiwan) and the JGA (Japan) while the associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI) are Associate Members. The IGBA is at the forefront of stimulating competitiveness and innovation in the pharmaceutical sector by providing high quality pro-competitive medicines to millions of patients around the world. Through its constituent member associations, the IGBA maintains constant dialogue with government authorities (including the European Commission for Europe) as well as with international institutions such as WTO, WIPO and WHO. More information: www.igbamedicines.org

 

MEDIA PARTNERS AND SPONSORS

CONTACT

Lucia Romagnoli W: www.egaevents.org